search
Back to results

Corticosteroid Therapy of Septic Shock - Corticus (Corticus)

Primary Purpose

Shock, Septic

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
hydrocortisone sodium succinate
Placebo
Sponsored by
Hadassah Medical Organization
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Shock, Septic focused on measuring Septic shock, Steroids, Hydrocortisone, Mortality, Reversal of shock, Adrenal insufficiency

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Clinical evidence of infection within the previous 72 hours (may be present longer than 72 hours) (a, b, c, or d - only 1 required) Presence of polymorphonuclear cells in a normally sterile body fluid (excluding blood); Culture or Gram stain of blood, sputum, urine or normally sterile body fluid positive for a pathogenic micro-organism; Focus of infection identified by visual inspection (e.g. ruptured bowel with the presence of free air or bowel contents in the abdomen found at the time of surgery, wound with purulent drainage); Other clinical evidence of infection - treated community acquired pneumonia, purpura fulminans, necrotising fascitis, etc. Evidence of a systemic response to infection as defined by the presence of two or more of the following signs within the previous 24 hours. These signs may be present longer than 72 hours. Fever (temperature >38.3°C) or hypothermia (rectal temperature < 35.6°C); Tachycardia (heart rate of >90 beat/min); Tachypnea (respiratory rate > 20 breaths/min, PaC02<32 mmHg) or patient requires invasive mechanical ventilation; Alteration of the WBC count >12,000 cells/mm3, <4,000 cells/mm3 or >10% immature neutrophils (bands). Evidence of shock defined by (A + B- both required within the previous 72 hours (may NOT be present longer than 72 hours). A. A systolic blood pressure < 90 mmHg or a decrease in SBP of more than 50 mmHg from baseline in previous hypertensive patients (for at least one hour) despite adequate fluid replacement OR need for vasopressors for at least one hour (infusion of dopamine ≥ 5 mcg/kg/min or any dose of adrenaline, noradrenaline, phenylephrine or vasopressin) to maintain a SBP ≥ 90 mmHg; B. Hypoperfusion or organ dysfunction which is not the result of underlying diseases or drugs, but is attributable to sepsis, including one of the following: Sustained oliguria (urine output < 0.5 ml/kg/hr for a minimum of 1 hour) Metabolic acidosis [pH of < 7.3, or a base deficit of > or = 5.0 mmol/L, or an increased lactic acid concentration (> 2 mmol/L)]. Arterial hypoxemia (Pa02/FI02<280 in the absence of pneumonia)(Pa02/FI02<200 in the presence of pneumonia). Thrombocytopenia - platelet count ≤ 100,000 cells/mm3. Acute altered mental status (Glasgow Coma Scale < 14 or acute change from baseline). 4. Informed Consent 5. Cortisol level at baseline and 60 minutes after 0.25 mg cosyntropin Exclusion Criteria: Pregnancy Age less than 18. Underlying disease with a prognosis for survival of less than 3 months. Cardiopulmonary resuscitation within 72 hours before study. Drug-induced immunosuppression, including chemotherapy or radiation therapy within 4 weeks before the study. Administration of chronic corticosteroids in the last 6 months or acute steroid therapy (any dose) within 4 weeks (including inhaled steroids). Topical steroids are not exclusions. HIV positivity. Presence of an advanced directive to withhold or withdraw life sustaining treatment (i.e. DNR). Advanced cancer with a life expectancy less than 3 months. Acute myocardial infarction or pulmonary embolus. Another experimental drug study within the last 30 days. Moribund patients likely to die within 24 hours. Patients in the ICU for more than 2 months at the time of the start of septic shock.

Sites / Locations

  • LKH Feldkirch
  • KH-BHS Linz
  • Krankenhaus der Barmherzigen Schwestern Ges. mbH
  • Universitaetsklinik fuer Innere Medizin II
  • Hopital St. Joseph
  • University Hospital Erasme
  • Cliniques Universitaires St. Luc, UCL
  • CHU Charleroi
  • Hopital Raymond Poincare
  • Hopital Lariboisiere
  • Hopital de Caen
  • Hopital Huriez
  • Hopital Caremeau
  • Hopital Saint-Antoine
  • Zentralklinikum Augsburg
  • Vivantes-Klinikum im Friedrichshain
  • Vivantes-Klinikum Spandau
  • Evangelisches Waldkrankenhaus Spandau
  • Charité Campus Mitte
  • St. Joseph Krankenhaus
  • Charité - Campus Benjamin Franklin
  • Vivantes-Klinikum Neukoelln
  • Charité - Campus Charité Mitte
  • Charité Campus Virchow -Klinikum
  • Charité Campus Virchow-Klinikum
  • Charité- Campus Virchow- Klinikum
  • Institute for Anaesthesia and Operative Intensive Care
  • University Hospital Dresden
  • Krankenhaus Hennigsdort
  • Friedrich-Schiller Universitaet
  • Klinikum Kemptern-Oberallegaeu
  • Klinikum Landshut
  • Klinikum Mannheim, University of Heidelberg
  • Staedtisches Krankenhaus Muenchen-Harlaching
  • Ludwig-Maximilian-Universitaet Muenchen
  • Klinikum Grosshadern, LMU Munich
  • Univesitaet Erlangen-Namberg
  • Klinikum Ernst von Bergman
  • Haemek Hospital
  • Hadassah Medical Organisation
  • Beilinson Medical Centre
  • Ichilov Hospital
  • Policlinico di Tor Vergata
  • Centro di Rianimazione Ospedale S.Eugenio
  • Renier de Graaf Hospital
  • Erasmus University Medical Centre
  • Hospital de St. Antonio do Capuchos
  • UCIP, Hospital de Desterro
  • Hospital de Egas Moniz
  • Aberdeen Royal Infirmary
  • Southend Hospital
  • Ipswich Hospital
  • Royal Lancaster Infirmary
  • The General Infirmary at Leeds
  • Bloomsbury Institute of Intensive Care Medicine
  • University of Manchester, Hope Hospital
  • Southampton General Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

1

2

Arm Description

hydrocortisone sodium succinate

Placebo

Outcomes

Primary Outcome Measures

28 day mortality in all the non-responders to ACTH (< or = 9 mcg/dl or 250 nmol/L post ACTH)

Secondary Outcome Measures

28 day all cause mortality in the total group.
28 day all cause mortality in responders.
One year mortality in nonresponders, total and responders.
ICU and hospital mortality.
Organ system failure reversal, especially shock.
Duration of ICU and total hospitalisation.

Full Information

First Posted
September 6, 2005
Last Updated
April 23, 2008
Sponsor
Hadassah Medical Organization
Collaborators
European Society of Intensive Care Medicine, International Sepsis Forum, The Gorham Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT00147004
Brief Title
Corticosteroid Therapy of Septic Shock - Corticus
Acronym
Corticus
Official Title
Corticosteroid Therapy of Septic Shock - Corticus. A Multi-National, Prospective, Double-Blind, Randomized, Placebo-Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2008
Overall Recruitment Status
Completed
Study Start Date
March 2002 (undefined)
Primary Completion Date
November 2005 (Actual)
Study Completion Date
November 2005 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Hadassah Medical Organization
Collaborators
European Society of Intensive Care Medicine, International Sepsis Forum, The Gorham Foundation

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the study is to determine whether steroids decrease 28-day mortality in patients with septic shock.
Detailed Description
The use of steroids in septic shock remains controversial. The purpose of this study is to determine whether hydrocortisone decreases 28-day mortality in patients with septic shock. The primary end point will be 28-day mortality in all the non-responders to ACTH (< or = 9 mcg/dl or 250 nmol/L post ACTH). Secondary endpoints will be 28 day all cause mortality in the total group and in responders, ICU and hospital mortality, one year mortality, organ system failure reversal especially shock, and duration of ICU and total hospitalisation. In a double-blinded fashion (randomized on a 1:1 basis), patients receive 50 mg intravenously every 6 hours for 5 days. After 5 days, treatment will be tapered with 50 mg given intravenously every 12 hours for days 6-8, then 50 mg every 24 hours for days 9-11, and then stopped. All concomitant treatments, including antibiotics, fluids, vasopressors and ancillary therapies will be given at the discretion of the primary care physician. Evidence-based guidelines for the management of severe sepsis and septic shock by the International Sepsis Forum (Intensive Care Med 2001;27:S124-S134) are encouraged to be followed. All serious adverse events (SAE) which occur between days 0 and 28, which are unexpected and/or considered possibly or probably related to the study medication, must be documented and reported within 24 hours to the Safety and Efficacy Monitoring Committee. Non-serious adverse events will be listed on the case report form if they are unexpected and believed to be related to the study drug during days 0 to 14. Specific adverse events which will be monitored closely because of their relationship to corticosteroids and shock are: Use of corticosteroids, i.e. gastrointestinal bleeding and superinfection; hyperglycemia, hypernatremia, muscular weakness, etc. Shock and use of vasopressors, i.e. stroke, acute myocardial infarction and peripheral ischemia. In addition, substudies will include harmonization of cortisol by comparing cortisol levels measured in local laboratories and a central laboratory, immune and neuro-endocrine interactions, neuromuscular weakness and cytokines.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Shock, Septic
Keywords
Septic shock, Steroids, Hydrocortisone, Mortality, Reversal of shock, Adrenal insufficiency

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
500 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
hydrocortisone sodium succinate
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Drug
Intervention Name(s)
hydrocortisone sodium succinate
Intervention Description
50 mg intravenous bolus every six hours for 5 days, then tapered to 50 mg intravenously every 12 hours for days 6-8, 50 mg every 24 hours for days 9-11 and then stopped
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
28 day mortality in all the non-responders to ACTH (< or = 9 mcg/dl or 250 nmol/L post ACTH)
Time Frame
28 days
Secondary Outcome Measure Information:
Title
28 day all cause mortality in the total group.
Time Frame
28 days
Title
28 day all cause mortality in responders.
Time Frame
28 days
Title
One year mortality in nonresponders, total and responders.
Time Frame
one year
Title
ICU and hospital mortality.
Time Frame
one year
Title
Organ system failure reversal, especially shock.
Time Frame
one year
Title
Duration of ICU and total hospitalisation.
Time Frame
one year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical evidence of infection within the previous 72 hours (may be present longer than 72 hours) (a, b, c, or d - only 1 required) Presence of polymorphonuclear cells in a normally sterile body fluid (excluding blood); Culture or Gram stain of blood, sputum, urine or normally sterile body fluid positive for a pathogenic micro-organism; Focus of infection identified by visual inspection (e.g. ruptured bowel with the presence of free air or bowel contents in the abdomen found at the time of surgery, wound with purulent drainage); Other clinical evidence of infection - treated community acquired pneumonia, purpura fulminans, necrotising fascitis, etc. Evidence of a systemic response to infection as defined by the presence of two or more of the following signs within the previous 24 hours. These signs may be present longer than 72 hours. Fever (temperature >38.3°C) or hypothermia (rectal temperature < 35.6°C); Tachycardia (heart rate of >90 beat/min); Tachypnea (respiratory rate > 20 breaths/min, PaC02<32 mmHg) or patient requires invasive mechanical ventilation; Alteration of the WBC count >12,000 cells/mm3, <4,000 cells/mm3 or >10% immature neutrophils (bands). Evidence of shock defined by (A + B- both required within the previous 72 hours (may NOT be present longer than 72 hours). A. A systolic blood pressure < 90 mmHg or a decrease in SBP of more than 50 mmHg from baseline in previous hypertensive patients (for at least one hour) despite adequate fluid replacement OR need for vasopressors for at least one hour (infusion of dopamine ≥ 5 mcg/kg/min or any dose of adrenaline, noradrenaline, phenylephrine or vasopressin) to maintain a SBP ≥ 90 mmHg; B. Hypoperfusion or organ dysfunction which is not the result of underlying diseases or drugs, but is attributable to sepsis, including one of the following: Sustained oliguria (urine output < 0.5 ml/kg/hr for a minimum of 1 hour) Metabolic acidosis [pH of < 7.3, or a base deficit of > or = 5.0 mmol/L, or an increased lactic acid concentration (> 2 mmol/L)]. Arterial hypoxemia (Pa02/FI02<280 in the absence of pneumonia)(Pa02/FI02<200 in the presence of pneumonia). Thrombocytopenia - platelet count ≤ 100,000 cells/mm3. Acute altered mental status (Glasgow Coma Scale < 14 or acute change from baseline). 4. Informed Consent 5. Cortisol level at baseline and 60 minutes after 0.25 mg cosyntropin Exclusion Criteria: Pregnancy Age less than 18. Underlying disease with a prognosis for survival of less than 3 months. Cardiopulmonary resuscitation within 72 hours before study. Drug-induced immunosuppression, including chemotherapy or radiation therapy within 4 weeks before the study. Administration of chronic corticosteroids in the last 6 months or acute steroid therapy (any dose) within 4 weeks (including inhaled steroids). Topical steroids are not exclusions. HIV positivity. Presence of an advanced directive to withhold or withdraw life sustaining treatment (i.e. DNR). Advanced cancer with a life expectancy less than 3 months. Acute myocardial infarction or pulmonary embolus. Another experimental drug study within the last 30 days. Moribund patients likely to die within 24 hours. Patients in the ICU for more than 2 months at the time of the start of septic shock.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Charles L Sprung, MD
Organizational Affiliation
Hadasah Medical Organization
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Djillali Annane, MD
Organizational Affiliation
Hopital Raymond Poincare
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Josef Briegel, MD
Organizational Affiliation
Ludwig-Maximilian-Universitaet Muenchen
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Didier Keh, MD
Organizational Affiliation
Charite Campus Virchow-Klinikum
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Rui Moreno, MD
Organizational Affiliation
Hospital de St. António dos Capuchos
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Didier Pittet, MD
Organizational Affiliation
University Hospital, Geneva
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Mervyn Singer, MD
Organizational Affiliation
University College, London
Official's Role
Study Director
Facility Information:
Facility Name
LKH Feldkirch
City
Feldkirch
ZIP/Postal Code
A-6800
Country
Austria
Facility Name
KH-BHS Linz
City
Linz
ZIP/Postal Code
A-4010
Country
Austria
Facility Name
Krankenhaus der Barmherzigen Schwestern Ges. mbH
City
Linz
ZIP/Postal Code
A-4010
Country
Austria
Facility Name
Universitaetsklinik fuer Innere Medizin II
City
Wien
ZIP/Postal Code
A 1090
Country
Austria
Facility Name
Hopital St. Joseph
City
Arlon
ZIP/Postal Code
B-6700
Country
Belgium
Facility Name
University Hospital Erasme
City
Brussels
ZIP/Postal Code
B-1070
Country
Belgium
Facility Name
Cliniques Universitaires St. Luc, UCL
City
Brussels
ZIP/Postal Code
B-1200
Country
Belgium
Facility Name
CHU Charleroi
City
Charleroi
ZIP/Postal Code
B-6000
Country
Belgium
Facility Name
Hopital Raymond Poincare
City
Paris
State/Province
Garches
ZIP/Postal Code
F-92380
Country
France
Facility Name
Hopital Lariboisiere
City
Paris
State/Province
Oarus
ZIP/Postal Code
F-75010
Country
France
Facility Name
Hopital de Caen
City
Caen
ZIP/Postal Code
14033
Country
France
Facility Name
Hopital Huriez
City
Lille
ZIP/Postal Code
F-59037
Country
France
Facility Name
Hopital Caremeau
City
Nimes
ZIP/Postal Code
30029 cedex 9
Country
France
Facility Name
Hopital Saint-Antoine
City
Paris
ZIP/Postal Code
F-75571
Country
France
Facility Name
Zentralklinikum Augsburg
City
Augsburg
ZIP/Postal Code
D-86155
Country
Germany
Facility Name
Vivantes-Klinikum im Friedrichshain
City
Berlin
ZIP/Postal Code
D - 10249
Country
Germany
Facility Name
Vivantes-Klinikum Spandau
City
Berlin
ZIP/Postal Code
D - 13585
Country
Germany
Facility Name
Evangelisches Waldkrankenhaus Spandau
City
Berlin
ZIP/Postal Code
D - 13589
Country
Germany
Facility Name
Charité Campus Mitte
City
Berlin
ZIP/Postal Code
D-10117
Country
Germany
Facility Name
St. Joseph Krankenhaus
City
Berlin
ZIP/Postal Code
D-12101
Country
Germany
Facility Name
Charité - Campus Benjamin Franklin
City
Berlin
ZIP/Postal Code
D-12200
Country
Germany
Facility Name
Vivantes-Klinikum Neukoelln
City
Berlin
ZIP/Postal Code
D-12313
Country
Germany
Facility Name
Charité - Campus Charité Mitte
City
Berlin
ZIP/Postal Code
D-13353
Country
Germany
Facility Name
Charité Campus Virchow -Klinikum
City
Berlin
ZIP/Postal Code
D-13353
Country
Germany
Facility Name
Charité Campus Virchow-Klinikum
City
Berlin
ZIP/Postal Code
D-13353
Country
Germany
Facility Name
Charité- Campus Virchow- Klinikum
City
Berlin
ZIP/Postal Code
D-13353
Country
Germany
Facility Name
Institute for Anaesthesia and Operative Intensive Care
City
Darmstadt
ZIP/Postal Code
D-64283
Country
Germany
Facility Name
University Hospital Dresden
City
Dresden
ZIP/Postal Code
D- 01307
Country
Germany
Facility Name
Krankenhaus Hennigsdort
City
Hennigsdorf
ZIP/Postal Code
D-16761
Country
Germany
Facility Name
Friedrich-Schiller Universitaet
City
Jena
ZIP/Postal Code
D - 07740
Country
Germany
Facility Name
Klinikum Kemptern-Oberallegaeu
City
Kempten
ZIP/Postal Code
D-87439
Country
Germany
Facility Name
Klinikum Landshut
City
Landshut
ZIP/Postal Code
D-84034
Country
Germany
Facility Name
Klinikum Mannheim, University of Heidelberg
City
Mannheim
ZIP/Postal Code
D- 68167
Country
Germany
Facility Name
Staedtisches Krankenhaus Muenchen-Harlaching
City
Muenchen
ZIP/Postal Code
D- 81545
Country
Germany
Facility Name
Ludwig-Maximilian-Universitaet Muenchen
City
Muenchen
ZIP/Postal Code
D-81366
Country
Germany
Facility Name
Klinikum Grosshadern, LMU Munich
City
Munich
ZIP/Postal Code
D-81377
Country
Germany
Facility Name
Univesitaet Erlangen-Namberg
City
Nurenberg
ZIP/Postal Code
D-90471
Country
Germany
Facility Name
Klinikum Ernst von Bergman
City
Potsdam
ZIP/Postal Code
D-14467
Country
Germany
Facility Name
Haemek Hospital
City
Afula
ZIP/Postal Code
18101
Country
Israel
Facility Name
Hadassah Medical Organisation
City
Jerusalem
ZIP/Postal Code
91120
Country
Israel
Facility Name
Beilinson Medical Centre
City
Petach Tikva
ZIP/Postal Code
491000
Country
Israel
Facility Name
Ichilov Hospital
City
Tel Aviv
ZIP/Postal Code
64239
Country
Israel
Facility Name
Policlinico di Tor Vergata
City
Roma
ZIP/Postal Code
00133
Country
Italy
Facility Name
Centro di Rianimazione Ospedale S.Eugenio
City
Roma
ZIP/Postal Code
00144
Country
Italy
Facility Name
Renier de Graaf Hospital
City
Delft
ZIP/Postal Code
2600 GA
Country
Netherlands
Facility Name
Erasmus University Medical Centre
City
Rotterdam
ZIP/Postal Code
3000 CA
Country
Netherlands
Facility Name
Hospital de St. Antonio do Capuchos
City
Lisboa
ZIP/Postal Code
1150
Country
Portugal
Facility Name
UCIP, Hospital de Desterro
City
Lisbon
ZIP/Postal Code
1150
Country
Portugal
Facility Name
Hospital de Egas Moniz
City
Lisbon
ZIP/Postal Code
1349-019
Country
Portugal
Facility Name
Aberdeen Royal Infirmary
City
Aberdeen
ZIP/Postal Code
AB25 2ZD
Country
United Kingdom
Facility Name
Southend Hospital
City
Essex
ZIP/Postal Code
SSO ORY
Country
United Kingdom
Facility Name
Ipswich Hospital
City
Ipswich
ZIP/Postal Code
IP4 5PD
Country
United Kingdom
Facility Name
Royal Lancaster Infirmary
City
Lancaster
ZIP/Postal Code
LA1 4RP
Country
United Kingdom
Facility Name
The General Infirmary at Leeds
City
Leeds
ZIP/Postal Code
LS1 3EX
Country
United Kingdom
Facility Name
Bloomsbury Institute of Intensive Care Medicine
City
London
ZIP/Postal Code
W1T 3AA
Country
United Kingdom
Facility Name
University of Manchester, Hope Hospital
City
Salford
ZIP/Postal Code
M6 8HD
Country
United Kingdom
Facility Name
Southampton General Hospital
City
Southampton
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
12761380
Citation
Annane D, Briegel J, Sprung CL. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003 May 22;348(21):2157-9. doi: 10.1056/NEJM200305223482123. No abstract available.
Results Reference
background
PubMed Identifier
18184957
Citation
Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008 Jan 10;358(2):111-24. doi: 10.1056/NEJMoa071366.
Results Reference
result
PubMed Identifier
22073145
Citation
Polito A, Sonneville R, Guidoux C, Barrett L, Viltart O, Mattot V, Siami S, Lorin de la Grandmaison G, Chretien F, Singer M, Gray F, Annane D, Brouland JP, Sharshar T. Changes in CRH and ACTH synthesis during experimental and human septic shock. PLoS One. 2011;6(11):e25905. doi: 10.1371/journal.pone.0025905. Epub 2011 Nov 3.
Results Reference
derived

Learn more about this trial

Corticosteroid Therapy of Septic Shock - Corticus

We'll reach out to this number within 24 hrs